Early switch from run-in with targeted to immunotherapy in advanced BRAF-positive melanoma: final results of the randomised phase II ImmunoCobiVem trialE. Livingstone, Dirk Schadendorf, P. Terheyden et al.|ESMO Open|2025Cited by 4
LBA45 Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trialD. Schadendorf, E. Livingstone, H. Gogas et al.|Annals of Oncology|2024Cited by 3
Genetic characterization and clinical outcome of melanoma of unknown primary (MUP) with comparison to melanoma with known primary (MKP)Georg Lodde, E. Livingstone, J. Dollani et al.|EJC Skin Cancer|2025Cited by 0